Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harel Dahari

Showing results (1-10 of 135) with videos related to

Pageof 14
Sort By:
The Lancet. Infectious Diseases|November 21, 2017
How to eliminate HCV in people who inject drugs in the USAHarel Dahari, Basmattee Boodram
Hepatology (Baltimore, Md.)|March 12, 2014
Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approachHarel Dahari, Scott J Cotler
Hepatology (Baltimore, Md.)|October 16, 2007
Hepatitis C virus kinetics in chimeric mice during antiviral therapyHarel Dahari, Alan S Perelson
World Journal of Gastroenterology|June 26, 2007
Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells lossHarel Dahari, Alan S Perelson
Mathematical Biosciences|March 19, 2018
Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamicsVladimir Reinharz, Harel Dahari, Danny Barash
Bulletin of Mathematical Biology|April 9, 2024
Mathematical Models of Early Hepatitis B Virus Dynamics in Humanized MiceStanca M Ciupe, Harel Dahari, Alexander Ploss
Journal of Hepatology|June 1, 2016
Resurrection of response-guided therapy for sofosbuvir combination therapiesHarel Dahari, Phillippe Halfon, Scott J Cotler
Scientific Reports|January 9, 2021
Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infectionSarah Kadelka, Harel Dahari, Stanca M Ciupe
Hepatology (Baltimore, Md.)|November 13, 2020
Letter to the Editor: Examining HBV-RNA Kinetics During NA Treatment-Are NAs Multifunctional Antiviral Agents?Harel Dahari, Andrew Vaillant, Scott J Cotler
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2011
Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapyJeremie Guedj, Harel Dahari, Alan S Perelson
Pageof 14

Showing results (1-10 of 135) with videos related to

Sort By:
Pageof 14
The Lancet. Infectious Diseases|November 21, 2017
How to eliminate HCV in people who inject drugs in the USAHarel Dahari, Basmattee Boodram
Hepatology (Baltimore, Md.)|March 12, 2014
Individualized treatment for patients with low HCV load (genotype 1): a viral kinetic approachHarel Dahari, Scott J Cotler
Hepatology (Baltimore, Md.)|October 16, 2007
Hepatitis C virus kinetics in chimeric mice during antiviral therapyHarel Dahari, Alan S Perelson
World Journal of Gastroenterology|June 26, 2007
Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells lossHarel Dahari, Alan S Perelson
Mathematical Biosciences|March 19, 2018
Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamicsVladimir Reinharz, Harel Dahari, Danny Barash
Bulletin of Mathematical Biology|April 9, 2024
Mathematical Models of Early Hepatitis B Virus Dynamics in Humanized MiceStanca M Ciupe, Harel Dahari, Alexander Ploss
Journal of Hepatology|June 1, 2016
Resurrection of response-guided therapy for sofosbuvir combination therapiesHarel Dahari, Phillippe Halfon, Scott J Cotler
Scientific Reports|January 9, 2021
Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infectionSarah Kadelka, Harel Dahari, Stanca M Ciupe
Hepatology (Baltimore, Md.)|November 13, 2020
Letter to the Editor: Examining HBV-RNA Kinetics During NA Treatment-Are NAs Multifunctional Antiviral Agents?Harel Dahari, Andrew Vaillant, Scott J Cotler
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2011
Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapyJeremie Guedj, Harel Dahari, Alan S Perelson
Pageof 14